Le Lézard
Classified in: Health
Subjects: PDT, TDS, FDA, FVT

Olympus Set to Demonstrate Newest Endoscopy System at DDW


The EVIS X1tm endoscopy system features two compatible gastrointestinal endoscopes and three new visualization technologies

CENTER VALLEY, Pa., May 4, 2023 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced today that, for the first time in the U.S., it will demonstrate the EVIS X1tm endoscopy system, its most advanced endoscopy system, at the Digestive Disease Week (DDW) annual meeting May 6-9 in Chicago.

The EVIS X1 endoscopy system recently received FDA 510(k) clearance along with two compatible gastrointestinal endoscopes: the GIF-1100 gastrointestinal videoscope indicated for use within the upper digestive tract and the CF-HQ1100DL/I colonovideoscope indicated for use within the lower digestive tract, which will also be displayed. The lightweight ErgoGriptm control section of these endoscopes has a rounded handle and easy-to-reach angulation control knobs and switches to accommodate users with small hands and support scope maneuverability.1

Features of the EVIS X1 endoscopy system2 include:

"We are very excited to share the advancements of our newest endoscopy system with gastroenterologists at the annual DDW meeting," said Richard Reynolds, President of the Medical Systems Group for Olympus America, Inc. "As a leading MedTech company, Olympus is driven to provide cutting-edge endoscopy systems that help physicians offer their patients the best care possible."

TXI, RDI, BAI-MAC and NBI technologies are not intended to replace histopathological sampling as a means of diagnosis. These are adjunctive tools for endoscopic examination that can be used to supplement Olympus white light imaging. 

Olympus encourages interested parties to visit the Olympus booth #3820 during DDW for hands-on demonstrations of the EVIS X1 endoscopy system. 

Olympus will offer other hands-on demonstrations, including the TJF-Q190V duodenoscope, VisiGlidetm guidewires and CleverCuttm3Vtm Sphincterotomes and EndoClot® Polysaccharide Hemostatic Spray (PHS). EndoClot PHS is a powder hemostat indicated for use in combination with other conventional techniques like clips to control bleeds.

Visitors to the booth will be able to see how EndoClot PHS works, watch clinical videos, and engage with physicians to understand its use in various procedures. Olympus last year entered into exclusive agreements with EndoClot Plus, Inc. to distribute EndoClot PHS and Submucosal Injection Solution (SIS) in the U.S. and EMEA markets. EndoClot PHS and SIS products are used in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas or early-stage cancers. 

Visit the Olympus booth during DDW or the gastroenterology product page for more information on the complete GI portfolio. Information about the EVIS X1 Endoscopy System will be available on the Olympus website.

A leading medical technology company, Olympus uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus' portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments. For more information, visit?medical.olympusamerica.com

1 Data on file with Olympus (internal testing in 2017)
2 Data on file (D00489968)
3 Data on file as of 02/Jul/2010

SOURCE Olympus


These press releases may also interest you

at 23:26
The Halal Economy Leadership Forum 2024 (HELF 2024) held recently in Riyadh, Saudi Arabia, set the stage for a momentous gathering of industry leaders, policymakers, and experts to advance discussions on the Halal Economy?a vital cornerstone of...

at 14:10
Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib...

at 12:25
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest real-world patient cohort review...

at 11:30
The Aesthetic Foundation, formerly known as the Aesthetic Surgery Education and Research Foundation (ASERF), proudly announces the election of Dr. Onelio Garcia Jr. "Oni", as its new President. Dr. Garcia's appointment heralds an exciting chapter for...

at 11:03
The Aesthetic Society proudly announces the appointment of Dr. Kiya Movassaghi, a board-certified plastic surgeon from Eugene, OR, as the President of The Aesthetic Society. Dr. Movassaghi's leadership will focus on strategically fortifying The...

at 09:05
Smart Meter, the leading supplier of Cellular Remote Patient Monitoring (RPM)tm solutions, has introduced a new version of the iGlucose, its patented cellular-connected glucose meter used by over 200,000 people with diabetes since 2019. The...



News published on and distributed by: